Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31292141 | 1.00 | MDM4 (0.45) | MDM4TP53MDM2TLR2CASP3 | |
| SCHEMBL20732314 | 1.00 | MDM4 (0.45) | MDM4TP53MDM2TLR2CASP3 | |
| SCHEMBL16412291 | 1.00 | MDM4 (0.45) | MDM4TP53MDM2TLR2CASP3 | |
| SCHEMBL30025559 | 1.00 | MDM4 (0.45) | MDM4TP53MDM2TLR2CASP3 | |
| SCHEMBL30097312 | 1.00 | MDM4 (0.45) | MDM4TP53MDM2TLR2CASP3 | |
| SCHEMBL20732317 | 0.97 | TLR2 (0.43) | MDM4TP53MDM2TLR2CASP3 | |
| SCHEMBL29511192 | 0.97 | TLR2 (0.43) | MDM4TP53MDM2TLR2CASP3 | |
| SCHEMBL29423583 | 0.93 | MDM2 (0.44) | MDM4TP53MDM2TLR2BACE1 | |
| SCHEMBL12658043 | 0.93 | MDM2 (0.44) | MDM4TP53MDM2TLR2BACE1 | |
| SCHEMBL30412459 | 0.93 | MDM2 (0.44) | MDM4TP53MDM2TLR2BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312419-B2 | Hemiasterlin derivative having cysteine residue | Sumitomo Pharma Co., Ltd. (JP) | 2025-05-27 | — | — | US | disclosed |
| EP-3666787-B9 | ANTIBODY-DRUG CONJUGATES INCLUDING HEMIASTERLIN DERIVATIVE | SUMITOMO PHARMA CO LTD (JP) | 2024-08-28 | — | — | EP | disclosed |
| CN-111032676-B | Antibody drug complexes comprising hamiltin derivatives | 住友制药株式会社 | 2024-08-23 | — | — | CN | disclosed |
| US-20240059732-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | Sumitomo Pharma Co., Ltd. (JP) | 2024-02-22 | — | — | US | disclosed |
| EP-3666787-B1 | ANTIBODY-DRUG CONJUGATES INCLUDING HEMIASTERLIN DERIVATIVE | SUMITOMO PHARMA CO LTD (JP) | 2024-02-21 | — | — | EP | disclosed |
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-24 | — | — | US | disclosed |
| US-20220144889-A1 | Hemiasterlin Derivative Having Cysteine Residue | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144889-A1 | Hemiasterlin Derivative Having Cysteine Residue | SHBG, CYP11A1, CYP11B1 | MDM4 2803/4885TP53 1696/4885MDM2 1464/4885 |
| US-12312419-B2 | Hemiasterlin derivative having cysteine residue | SHBG, CYP11A1, CYP11B1 | MDM4 2803/4885TP53 1696/4885MDM2 1464/4885 |
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | HSD3B2, HSD3B1, HSD11B2 | MDM4 4109/4885TP53 3752/4885MDM2 4097/4885 |
| US-20240059732-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | HSD3B2, HSD3B1, HSD11B2 | MDM4 4109/4885TP53 3752/4885MDM2 4097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.